Musculoskeletal infection (MSKI) — including implant-associated infection, such as periprosthetic joint infection and fracture-related infection — remains one of the most challenging complications in orthopedic surgery. Treatment failure is driven by bacterial persistence across protected niches: biofilm, immune-shielded abscess communities, and bacteria residing within bone and host cells. These compartments evade conventional antibiotics and are the central barrier to effective treatment. The MSKI Laboratory integrates molecular biology, immunology, preclinical models, and advanced imaging to define mechanisms of persistence and develop targeted therapeutics.




Anti-DNABII Monoclonal Antibody Therapy for Periprosthetic Joint Infection

Biofilms render bacteria up to 8,000-fold more tolerant to antibiotics and are the central driver of treatment failure in implant-associated infection. DNABII proteins crosslink extracellular DNA (eDNA) at critical junctions, serving as the structural linchpin of the biofilm matrix. Anti-DNABII monoclonal antibodies sequester these proteins, causing rapid collapse of the biofilm scaffold and liberating bacteria from the biofilm that are sensitized to conventional antibiotics and exposed to host immune clearance.

Clinically relevant mouse models of implant-associated infection, paired with in vitro biofilm systems and zone-of-inhibition assays, quantify antimicrobial efficacy from the bench to preclinical testing.

Cell and molecular biology platforms dissect intracellular bacterial persistence, immune evasion mechanisms, and tissue-resident host defense.

High-resolution scanning electron microscopy characterizes implant surface topography, coating performance, biofilm, and bacterial adhesion at the material interface.

Micro-CT and plain X-ray imaging enable serial assessment of peri-implant bone remodeling, osteolysis, and infection-associated pathology over the disease course.

In vivo bioluminescence imaging of engineered luminescent bacterial strains permits real-time, non-invasive tracking of bacterial burden at the implant site, quantifying infection dynamics and therapeutic response within the same animal over time.

Histologic & immunohistochemical analyses characterize infection-associated tissue pathology, inflammatory cell infiltration, and bacteria and biofilm presence.

Biomarker discovery, diagnostics, and therapeutic evaluation.